Inicio › Enfermedad de Crohn › Indiana
Ensayos clínicos de Enfermedad de Crohn en Indiana
13 estudios sobre Enfermedad de Crohn buscan participantes en Indiana.
Ciudades en Indiana
Texto oficial del estudio (inglés)
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
- Indiana University Health University Hospital ( Site 5022), Indianapolis
ReclutandoFase 3
Edades de 16 a 80 · Todos los sexos · Actualizado el 10 nov 2026 · NCT06430801Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
- Indiana University Health University Hospital, Indianapolis
- Gastroenterology Health Partners, New Albany
ReclutandoFase 3
Edades de 18 a 70 · Todos los sexos · Actualizado el 4 nov 2026 · NCT06937099A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
- IU Health University Hospital, Indianapolis
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT07196722A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants
- Riley Hospital for Children, Indianapolis
ReclutandoFase 3
Edades de 3 en adelante · Todos los sexos · Actualizado el 3 nov 2026 · NCT06663332A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Riley Hospital for Children, Indianapolis
ReclutandoFase 3
Edades de 2 a 17 · Todos los sexos · Actualizado el 3 nov 2026 · NCT05923073A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting
- Riverview Health, Westfield
ReclutandoFase 4
Edades de 18 a 80 · Todos los sexos · Actualizado el 28 oct 2026 · NCT06581328Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
- Gastroenterology Health Partners /ID# 284145, New Albany
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 27 oct 2026 · NCT07697456A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
ReclutandoFase 3
Edades de 16 a 80 · Todos los sexos · Actualizado el 21 oct 2026 · NCT07184944An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease
- Gastroenterology Health Partners, PLLC - New Albany-Site Number: 8400100, New Albany
ReclutandoFase 3
Edades de 16 a 80 · Todos los sexos · Actualizado el 21 oct 2026 · NCT07184931A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
- Indiana University Health Riley Hospital for Children /ID# 256454, Indianapolis
ReclutandoFase 3
Edades de 2 a 17 · Todos los sexos · Actualizado el 20 oct 2026 · NCT05995353A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
- Riley Childrens Hospital, Indianapolis
ReclutandoFase 3
Edades de 2 a 17 · Todos los sexos · Actualizado el 7 oct 2026 · NCT05509777Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
- Indiana University Health University Hospital /ID# 278129, Indianapolis
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 25 sept 2026 · NCT06548542Precise Infliximab Exposure and Pharmacodynamic Control
- Riley Hospital for Children, Indianapolis
ReclutandoFase 2/3
Edades de 6 a 22 · Todos los sexos · Actualizado el 5 may 2026 · NCT05660746De ClinicalTrials.gov, datos obtenidos el 15 nov 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.